Falling Walls Venture is a global platform to showcase the entrepreneurial potential in science. The format provides a stage for pioneering science-based start-ups who have successfully turned science into business, proving how entrepreneurial solutions can help solve today’s most pressing challenges.
Throughout the year, universities and institutions from all over the world are called upon to nominate the most innovative science start-up for the competition. The most promising young companies, carefully selected by our Advisory Board, are invited to pitch on the Falling Walls Venture stage in Berlin on 7 November. They also gain access to the whole Falling Walls Science Summit as well as to exclusive networking events and the Falling Walls Community.
Meet the Falling Walls Venture Advisory Board
Meet the Falling Walls Venture Advisory Board 1/3
Meet the Falling Walls Venture Advisory Board 2/3
Meet the Falling Walls Venture Advisory Board 3/3
A high-calibre jury of international experts, investors, and corporate innovation leaders, chaired by Stefan von Holtzbrinck, CEO of Holtzbrinck Publishing Group, will select one of the start-ups as the “Falling Walls Science Breakthrough of the Year Science Start-Ups”. The selected start-up gets the chance to pitch their breakthrough innovation on the big stage on 9 November, the anniversary of the historic fall of the Berlin Wall, alongside other outstanding researchers who will each showcase their work.
Falling Walls Science Start-up Breakthrough of the Year 2022: Simon Gröblacher, Qphox
“In Falling Walls Venture, start-ups find an enthusiastic and supportive community from all over the world!”
Christian Elias Schneider – Universität Basel
“One of the most anticipated events for top start-ups.“
Carsten Mahrenholz – Coldplasmatech
“The level of energy you get from Falling Walls is just incredible.”
Alison Mitchell – Springer Nature
“We met the Falling Walls Venture Winner, T3 Pharmaceuticals, at the event and were immediately convinced by the scientific concept – so we participated in the second round of financing.”
Frank Kalkbrenner – Boehringer Ingelheim Venture Fund
